US Has Opportunity To Lead On Ophthalmic Biosimilars

Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report

 
• By David Wallace
  
Turning Point Sign
Cardinal Health says 2022 will be a turning point for US biosimilars • Source: YAY Media AS / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products